Keyphrases
Therapeutic Potential
100%
Doxorubicin
100%
Histone Deacetylase Inhibitor (HDACi)
100%
AN-7
100%
Mycosis Fungoides
100%
Sézary Syndrome
100%
Suberoylanilide Hydroxamic Acid
70%
Peripheral Blood Lymphocytes
20%
Hut78
20%
Cell Death
10%
Adverse Effects
10%
Low Dose Rate
10%
Apoptosis
10%
Therapeutic Agents
10%
Western Blot
10%
T-cell Lymphoma
10%
Viability Assay
10%
Viable Cells
10%
Apoptosis Assay
10%
Combination Treatment
10%
Histone Deacetylase 1 (HDAC1)
10%
Healthy Normal
10%
Acetylated Histone H3
10%
Diethyl Phosphite
10%
Drug-induced Apoptosis
10%
Anticancer Effect
10%
Romidepsin
10%
Selective Anticancer Activity
10%
Medicine and Dentistry
Vorinostat
100%
Histone Deacetylase Inhibitor
100%
Mycosis fungoides
100%
Sezary Syndrome
100%
Doxorubicin
100%
Mycosis Fungoides/Sezary Syndrome Cell Line
71%
Programmed Cell Death
28%
Lymphocyte
28%
Cell Line
28%
down Regulation
14%
Antineoplastic Activity
14%
Therapeutic Agent
14%
Adverse Event
14%
Western Blot
14%
Apoptosis Assay
14%
Cell Death
14%
HDAC1
14%
Romidepsin
14%
Histone H3
14%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Histone Deacetylase Inhibitor
100%
Sezary Syndrome
100%
Mycosis fungoides
100%
Vorinostat
70%
Viability Assay
10%
Western Blot
10%
Apoptosis Assay
10%
Adverse Event
10%
Histone Deacetylase 1
10%
Romidepsin
10%
Histone H3
10%